Merck & Co is pushing forward with its Phase 3 program to test the efficacy of MK-0616, an oral cholesterol-lowering drug that has shown promise in mid-stage trials by matching the effects of approved injectable competitors. This developme…
Watch On Demand Are you looking to gain a competitive edge in the life sciences industry and accelerate your business development and partnership success? Look no further than Synapse! In th…
Spinal Muscular Atrophy (SMA) affects one in 8,000 people worldwide and is a genetic disease that affects the central nervous and peripheral nervous systems, along with muscle movement. It’s progressive, meaning it gets worse as time goes on. L…
